IRON Key Statistics, Chart & Performance
The current stock price of IRON is 71.99 USD. In the past month the price decreased by -4.57%. In the past year, price increased by 33.07%.
IRON Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IRON. When comparing the yearly performance of all stocks, IRON turns out to be only a medium performer in the overall market: it outperformed 56.78% of all stocks.
IRON Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IRON. IRON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IRON Financial Highlights
Over the last trailing twelve months IRON reported a non-GAAP Earnings per Share(EPS) of -5.35. The EPS decreased by -36.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.73% | ||
| ROE | -31.59% | ||
| Debt/Equity | 0.05 |
IRON Forecast & Estimates
19 analysts have analysed IRON and the average price target is 123.25 USD. This implies a price increase of 71.2% is expected in the next year compared to the current price of 71.99.
IRON Ownership
IRON Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.21 | 393.136B | ||
| AMGN | AMGEN INC | 16.27 | 196.357B | ||
| GILD | GILEAD SCIENCES INC | 17.47 | 182.665B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.62 | 117.594B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.77 | 79.341B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.11 | 42.669B | ||
| INSM | INSMED INC | N/A | 31.681B | ||
| NTRA | NATERA INC | N/A | 29.21B | ||
| BIIB | BIOGEN INC | 12.57 | 27.736B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.15 | 20.376B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IRON
Company Profile
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Company Info
DISC MEDICINE INC
321 Arsenal Street, Suite 101
Watertown MASSACHUSETTS US
Employees: 125
Phone: 16176749274
DISC MEDICINE INC / IRON FAQ
Can you describe the business of DISC MEDICINE INC?
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. The company is headquartered in Watertown, Massachusetts and currently employs 84 full-time employees. The company went IPO on 2020-08-12. The firm's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. The company is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
What is the stock price of DISC MEDICINE INC today?
The current stock price of IRON is 71.99 USD. The price decreased by -3.69% in the last trading session.
Does IRON stock pay dividends?
IRON does not pay a dividend.
What is the ChartMill rating of DISC MEDICINE INC stock?
IRON has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about DISC MEDICINE INC (IRON) stock?
19 analysts have analysed IRON and the average price target is 123.25 USD. This implies a price increase of 71.2% is expected in the next year compared to the current price of 71.99.
How is the valuation of DISC MEDICINE INC (IRON) based on its PE ratio?
DISC MEDICINE INC (IRON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.35).
What is DISC MEDICINE INC worth?
DISC MEDICINE INC (IRON) has a market capitalization of 2.72B USD. This makes IRON a Mid Cap stock.